| Overview |
| bs-9557R-APC |
| GLTPD2 Polyclonal Antibody, APC Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| APC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GLTPD2 |
| 171-270/291 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| glycolipid transfer protein domain-containing protein 2; Glycolipid transfer protein domain containing 2; GLTD2_HUMAN. |
| The GLTP (glycolipid transfer protein) superfamily is defined by a unique lipid transfer/binding fold (GLTP fold) that accelerate glycolipid intermembrane transfer. GLTPD2 is a 291 amino acid protein that belongs to the GLTP family. The gene encoding GLTPD2 maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, p53 and BRCA1. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Neurofibromatosis, a condition characterized by neural and epidermal lesions, and dysregulated Schwann cell growth are both linked to mutations on chromosome 17. Alexander disease, Birt-Hogg-Dube syndrome and Canavan disease are also associated with chromosome 17. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz